Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

AI-09 is safe, effective, and reduces wrinkles for up to 6 months.

This case report describes a patient with glaucoma who developed reversible hyperpigmentation and hypertrichosis after using bimatoprost eye drops, aiming to explore prostaglandin analogues' potential roles in hair and depigmentation therapies.

This study found that oral minoxidil can improve hair and eyebrow growth and increase the density of the frontotemporal hairline in patients with FFA, though adverse effects were reported by a third of participants.

This promotional content discusses hair transplantation options near Lauderhill and reports no new research findings; readers are encouraged to speak with a specialist for more information.

This study found that while bimatoprost was safe for 16 weeks, it was not effective for eyelash growth in patients with significant loss due to alopecia areata, though some with less loss experienced growth.

This article discusses various options for camouflaging hair loss involving the scalp, eyebrows, and eyelashes, and reports no new clinical findings.

This overview describes the Dermatologic Surgery journal's extensive focus on cosmetic and reconstructive procedures but reports no new research findings.

This study demonstrates that mouse eyelashes can effectively model human eyelash growth to analyze morphology, development, and the effects of growth-stimulatory agents like bimatoprost.

This study reports that a novel multi-compound Blend, tested on ex vivo human hair follicles, promotes hair growth by enhancing elastin deposition and dermal papilla inductivity more effectively than isopropyl cloprostenate, suggesting benefits through elastogenesis and modulation of Wnt signaling.

This study uncovered that bimatoprost, a prostaglandin analog, promotes hair growth by activating hair follicle progenitor cells through two pathways: the PTGFR-MAPK signaling axis and an unexpected IGF1R-PCAD-AKT signaling axis, suggesting new potential targets for treating hair disorders.

In this study, a novel topical bimatoprost formulation (BIM-TF#5) significantly enhanced hair regrowth and increased dermal drug deposition in both human skin models and an androgenic alopecia mouse model compared to previous preparations.

This study developed a spring-driven microneedle booster that improved early and cumulative delivery of minoxidil, accelerating hair regrowth compared to traditional roller methods in an androgenetic alopecia model.

In a real-world study, baricitinib was effective for scalp, eyebrow, and eyelash regrowth in patients with alopecia areata, showing clinically meaningful improvements as early as 3 months and increasing up to 12 months; satisfaction and perceived improvement were also high among participants.

This study found that treatment with baricitinib 4 mg over 52 weeks led to clinically meaningful regrowth of eyebrows and eyelashes in patients with alopecia areata, even without complete scalp hair regrowth.

This study found that VB-1, a vitexin compound, may promote hair follicle growth by enhancing Wnt/β-catenin signaling in human dermal papilla cells in vitro.

This study reports that a water-soluble microneedle patch with minoxidil-loaded microspheres showed similar or better hair regeneration effects in mice with less frequent application compared to daily topical minoxidil.

This study highlights fat grafting and nanofat as promising options for treating dark circles, offering benefits in improving both volume and skin quality through a single-stage procedure with long-lasting outcomes.

This study found that white wax and its extract significantly promoted hair growth in a mouse model of androgenetic alopecia, outperforming finasteride by inhibiting 5α-reductase activity and enhancing cellular proliferation.

In this study, bimatoprost 0.03% was effective and well-tolerated for improving eyelash hypotrichosis in healthy adolescents, but not for those with the condition due to chemotherapy or alopecia areata.

In this study, AMP-303 injections demonstrated a trend toward increasing non-vellus hair count in men with mild to moderate androgenetic alopecia, notably showing a 14.5% peak increase at 60 days compared to saline, with effects lasting up to five months.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

This study reviewed the outcomes of a limited incision lateral brow lift technique, reporting that the procedure safely resolved lateral brow hooding with a low revision rate in 150 patients, and observed no permanent nerve injuries.

In this research letter from the British Journal of Dermatology, the authors explore the use of topical tofacitinib to treat alopecia areata affecting facial hair, but specific results are not reported in the abstract.

In a study on nude mice, topical application of Chrysanthemum zawadskii extracts stimulated hair growth and increased hair follicle numbers, suggesting potential for alopecia therapy.

In this study, a patch with microneedles regrew hair in shaved mice within six days, suggesting potential for treating hair loss in humans.

This study aims to provide a practical guide for managing common causes of madarosis, highlighting the need to identify underlying causes to ensure effective treatment for eyelash and eyebrow loss.